Pharmacological strategies for sexual recovery in men undergoing antipsychotic treatment
| Autor: | Tommaso B. Jannini, Andrea Sansone, Rodolfo Rossi, Giorgio Di Lorenzo, Massimiliano Toscano, Alberto Siracusano, Emmanuele A. Jannini |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Male
brexpiprazole Pharmacology prolactin drug treatment General Medicine Risperidone compliance antipsychotic schizophrenia Sexual Dysfunction Physiological aripiprazole Psychotic Disorders Settore MED/25 sexual dysfunction Humans management strategies Pharmacology (medical) Amisulpride dopamine Antipsychotic Agents |
| Zdroj: | Expert Opinion on Pharmacotherapy. 23:1065-1080 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1080/14656566.2022.2071124 |
| Popis: | First- and second-generation antipsychotics are highly accountable for causing a plethora of medical side effects, ranging from metabolic imbalances to sexual dysfunction (SD), that frequently undermine patient-doctor relationships. Nevertheless, to date antipsychotics are one of the best treatment options for dealing with numerous either acute or chronic conditions like agitation, suicidality, depression, dementia, and of course psychosis. For these reasons, clinicians need to handle them wisely to preserve patients' sexual health, avoid poor therapeutic adherence and prevent high rates of therapy drop-out.This article reviews the literature on pharmacologic approaches for management strategies in men who are administered with antipsychotics and developed SD. The etiology of antipsychotic-induced SD is also discussed.Clinicians must consider sexual life as a major health domain. To do so, a first step would be to measure and monitor sexual function by means of psychometric tools. Secondly, primary prevention should be conducted when choosing antipsychotics, i.e. picking sex-sparing compounds like aripiprazole or brexpiprazole. Thirdly, if sexolytic compounds cannot be dismissed, such as first-generation antipsychotics, risperidone, paliperidone, or amisulpride, then aripiprazole 5-20 mg/day adjunctive therapy has proven to be most effective in normalizing prolactin levels and consequently treating antipsychotic-induced SD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|